Medline Inc. (MDLN) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. At $44.44, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: largest GPOs (69.0%); Concentration risk — Customer: Prime Vendor agreements (63.4%).
Medline is the largest provider of med-surg products and supply chain solutions, distributing approximately 335,000 products through Medline Brand and Supply Chain Solutions segments to hospitals and all care settings. Active Prime Vendor agreements generated approximately 63.4%... Read more
Sell if holding. At $44.44, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: largest GPOs (69.0%); Concentration risk — Customer: Prime Vendor agreements (63.4%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerlargest GPOs69%10-K Item 1A: '69% of consolidated net sales...our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.'
- HIGHCustomerPrime Vendor agreements63%10-K Item 1A: 'Our active Prime Vendor agreements as of December 31, 2025 generated approximately 63.4% ($18.0 billion) of net sales'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $44.44, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: largest GPOs (69.0%); Concentration risk — Customer: Prime Vendor agreements (63.4%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $41.62. Score 5.1/10, moderate confidence.
Take-profit target: $48.17 (+8.4% upside). Prior stop was $41.62. Stop-loss: $41.62.
Concentration risk — Customer: largest GPOs (69.0%); Concentration risk — Customer: Prime Vendor agreements (63.4%); Thin upside margin: 8.4%.
Medline Inc. trades at a P/E of 31.1 (forward 26.9). TrendMatrix value score: 6.1/10. Verdict: Sell.
33 analysts cover MDLN with a consensus score of 4.2/5. Average price target: $54.
What does Medline Inc. do?Medline is the largest provider of med-surg products and supply chain solutions, distributing approximately 335,000...
Medline is the largest provider of med-surg products and supply chain solutions, distributing approximately 335,000 products through Medline Brand and Supply Chain Solutions segments to hospitals and all care settings. Active Prime Vendor agreements generated approximately 63.4% of 2025 net sales, with 69% of consolidated net sales from hospitals under contracts with Vizient, HealthTrust, and Premier GPOs.